Roche erleidet Rücksetzer bei Blasenkrebs

As the company announced on Friday, the goals in the phase III study for Tecentriq were not achieved.
(AWP) Roche (ROG 323.5 -1.19%) has been disappointed with its immunotherapeutic agent Tecentriq in the treatment of a specific type of bladder cancer. As the group announced on Friday, the goals set in the phase III IMvigor010 study were not achieved.

The aim of the study was to prolong disease-free survival in patients suffering from muscle-invasive bladder cancer (MIUC) and who were treated with Tecentriq as adjuvant monotherapy, i.e. after the operation. This goal was reportedly missed. Levi Garraway, chief medical officer and head of global product development, said the release disappointed with the setback.

Switzerland approval for Kadcyla

At the same time, Roche reported on Friday morning that the Swiss Agency for Therapeutic Products (Swissmedic) approved the cancer drug Kadcyla in another indication. It can now also be used in patients suffering from an early form of HER2-positive breast cancer.

Specifically, kadcyla (trastuzumab emtansine) can be used as monotherapy for the adjuvant treatment of patients with early HER2-positive breast cancer who, after preoperative taxane-containing chemotherapy in combination with at least trastuzumab as HER2-directed therapy, a residual disease in the breast and / or have the lymph node.